Pfizer Recalls Prempro Tablets Due to Dissolution Specification Failures
Pfizer is recalling specific lots of Prempro tablets because they may not meet dissolution specifications for conjugated estrogens.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The source text identifies this as an FDA Class III recall, which the rubric defines as typically scoring 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Pfizer Inc. is recalling Prempro (conjugated estrogens/medroxyprogesterone acetate tablets) 0.625 mg/2.5 mg. The recall involves 432,657 blister cards, each containing 28 tablets, distributed nationwide and in Puerto Rico. The affected lots are E67324 and E96152, with an expiration date of 06/13.
The recall was initiated because certain lots of the product may not meet the dissolution specification for conjugated estrogens. This is a Class III recall, indicating that the violation is not likely to cause adverse health consequences.
Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed above. If the product matches the recalled description, it should be returned to the pharmacy or supplier for replacement or refund.
The recalled product
- Product
- Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/2.5 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA, NDC 0046-0875-11
- Manufacturer
- Pfizer Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 432,657
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lots: E67324 & E96152 Exp: 06/13
Distribution
Part of a larger recall action
This product is one of 2 recalled by Pfizer Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Pfizer Inc.
See all →- HighSodium bicarbonate injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighEpinephrine injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighBicillin L-A 2.4 million unit vials recalled after particulates found
FDA (Drugs) · 2025-08-06
- HighBicillin L-A penicillin vials recalled after particulates found during visual inspection
FDA (Drugs) · 2025-08-06
- ModerateDobutamine Injection Recall Due to Discoloration and Cracked Vials
FDA (Drugs) · 2025-07-02
Same hazard · quality control
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateDuoGlide Short-Term Dialysis Catheter recall due to deficient manufacturing
FDA (Devices) · 2026-07-08
- ModeratedirectCHECK whole blood control labeled with incorrect performance range
FDA (Devices) · 2026-06-24
- HighAmyloid plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11
- HighpTau 217 plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11